early and affordable treatment for COVID-19
Early-stage
Biotech Company
Operations based in USA and Colombia
About
Rivanima Therapeutics is an early-stage, privately owned Biotech Company bringing affordable therapeutic solutions to COVID-19 & developing a portfolio of solutions to address other viral diseases using well-known drugs approved for other indications, in different pharmaceutical forms and/or new routes of administration; for human medical conditions that require more effective therapeutic interventions than those currently available
We leverage old drugs, finding new uses and therapeutic options, this is a proven approach that holds the potential to complement traditional drug discovery by mitigating the high expense and time‐related costs and risks associated with new chemical entities, furthermore, this holds the potential to bring medications with known safety profiles to new patient populations
Rivanima is also working on innovative science for diagnostics in viral replication
At Rivanima, we are developing therapies and solutions that have the potential to transform the lives of people with viral infectious diseases, in our business model, we will be offering opportunities to biotech and pharmaceutical companies, who will obtain distribution rights licenses from us to sell our products for individual geographical regions. Involving a relatively little expenditure, this approach will enable Rivanima to collaborate with partners with geographical knowledge and reach access to patients for our portfolio globally.
Meet our
Team
We operate a lean and agile business with an experienced core team of executives based in the USA and Latin America
Janeth Mora
PharmD
CEO
An executive with over two decades of leadership experience in pharmaceutical business and corporate development and marketing in emerging economies. Serving in various leadership positions at Pfizer – including her role as the Regional Marketing Director for Emerging Markets – has equipped Janeth with the necessary expertise to lead our startup from clinic to market. Her deep knowledge in establishing, customizing and supporting implementation of global and regional commercialization strategies will be of crucial value to Rivanima’s product development and global commercialization readiness. She is a trained negotiator from Harvard Law School and a Certified Professional Business and Life Coach. Janeth holds various degrees in Pharmacy, Management, Finance, Marketing from Universidad Nacional de Colombia, Columbia University, Universidad de los Andes and New York University.
Janeth and her family live in South FL
Dr. Carlos Riveros
MD
Founder – CMO
Dr. Carlos Riveros is an Internal Medicine Board Certified Doctor with more than 30 years of experience in the medical field. Graduated from medical school at the Universidad Militar Nueva Granada in Bogota, Colombia, Internal Medicine from Hospital Universitario de Cartagena and subsequently moved to USA where he completed an Internal Medicine residency program at the Pinnacle Health System Hospital in Harrisburg, PA. Later moved to Miami, FL with Tenet Health where he started a private practice. Dr. Riveros continued teaching activities at Mount Sinai Internal Medicine Residency program and at Larking Community Hospital Internal Medicine program for some years. Dr. Riveros’ practice increased rapidly and became United Medical Specialties, currently with 2 offices, in Coral Gables and Hialeah.
For the last 2 years, during this SARS-COV-2 Virus pandemic, Dr. Riveros has been working in developing a new medication, administered via nebulization that reduces viral replication when administered during the first days of symptoms. Has recently founded Rivanima Therapeutics, where this and other repurposed medications would be developed.
Carlos R. Olarte
B.S.E, J.D.
CIPO
Carlos is a founding partner of OlarteMoure, a 160+ person IP and Competition Law firm based in Bogota, Colombia, with offices in Medellin, Barranquilla, Bucaramanga and Tokyo. His 30 year practice focuses on patent law, including drafting, prosecution, litigation, monetization and transactional matters. A good portion of this practice focuses on the pharmaceutical and life sciences industry. Another important client base includes local universities and research-intensive early stage start-ups.
He graduated from Duke University (1990), where he majored in Biomedical and Mechanical Engineering. He subsequently received his J.D. from Chicago-Kent College of Law, IIT (1993) and later convalidated his law degree in Colombia at the Universidad Javeriana in Bogota (1994).
He lives in Bogota with his wife and two sons.
Juan D. Martínez
J.D.
Growth & Business Development
Juan attended Law school at Universidad de los Andes in Colombia, also pursued studies in Management and Chinese language and culture at Nankai University in China. He graduated as a Juris Doctor (JD) in 2015. Since then, Juan has been working in promoting and structuring several foreign investment greenfield and brownfield projects both in pharmaceutical and technology ventures in Colombia.
During 2020, Juan provided legal and strategic advice for a Colombian R&D center focused on neurological disorders, in the co-development of a medicine with a Neurological lab based in New York to reduce refractory epilepsy seizures using repurposed drugs.
In 2021, joined OlarteMoure, an IP law firm based in Colombia, to lead the Project Structuring Area for IP-based startups where he supports its growth, funding and go-to-market strategy.
Our Product
Nebuliv
Completed double blind, randomized, placebo-controlled Proof-of-Concept study (NCT04595136), that demonstrated a statistically significant difference in the reduction of SARS-COV-2 viral replication measured by count of Sub-genomic Messenger RNA (sg MRNA) in the participants receiving nebulized ivermectin when compared to placebo.